EGFR inhibition in the treatment of non-small cell lung cancer

Drug Development Research

Volumn 69, Issue 6, 2008, Pages 359-372

  Gerber, David E ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

Epidermal growth factor receptor; Monoclonal antibodies; Non small cell lung cancer; Targeted therapy; Tyrosine kinase inhibitors

Indexed keywords

ANTIBIOTIC AGENT; BCR ABL PROTEIN; BEVACIZUMAB; CARBOPLATIN; CETUXIMAB; CISPLATIN; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EPIDERMAL GROWTH FACTOR RECEPTOR 4; EPIDERMAL GROWTH FACTOR RECEPTOR ANTIBODY; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; GEFITINIB; GEMCITABINE; IMATINIB; IMMUNOGLOBULIN G1; IMMUNOGLOBULIN G2; LAPATINIB; NAVELBINE; PACLITAXEL; PANITUMUMAB; PLACEBO; PROTEIN TYROSINE KINASE; STEROID;

ACNE; ANTINEOPLASTIC ACTIVITY; CANCER INHIBITION; CANCER RESISTANCE; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG DESIGN; DRUG HYPERSENSITIVITY; DRUG TARGETING; GENE MUTATION; HUMAN; LUNG NON SMALL CELL CANCER; NONHUMAN; OUTCOME ASSESSMENT; PREDICTION; RASH; REVIEW; SIGNAL TRANSDUCTION;

EID: 57749097618     PISSN: 02724391     EISSN: 10982299     Source Type: Journal    
DOI: 10.1002/ddr.20268     Document Type: Review

References (144)

1. Adjei AA. 2006. Novel combinations based on epidermal growth factor receptor inhibition. Clin Cancer Res 12(Pt 2):4446s-4450s.
2. Ahn MJ, Park BB, et al. 2008. Are there any ethnic differences in molecular predictors of erlotinib efficacy in advanced non-small cell lung cancer? Clin Cancer Res 14:3860-3866.
3. Ahrendt SA, Decker PA, et al. 2001. Cigarette smoking is strongly associated with mutation of the K-ras gene in patients with primary adenocarcinoma of the lung. Cancer 92:1525-1530.
4. Albain KG, Green SJ, Ravdin PM, Cobau CD, Levine EG, Ingle JN, Pritchard KI, Schneider DJ, Abeloff MD, Norton L, Henderson IC, Lew D, Livingston RB, Martino S, Osborne CK. 2002. Adjuvant chemohormonal therapy for primary breast cancer should be sequential instead of concurrent: initial results from intergroup trial 0100 (SWOG-8814). Proc Am Soc Clin Oncol 21:abstract 143.
5. Asahina H, Yamazaki K, et al. 2006. A phase II trial of gefitinib as first-line therapy for advanced non-small cell lung cancer with epidermal growth factor receptor mutations. Br J Cancer 95:998-1004.
6. Azzariti A, Xu JM, et al. 2004. The schedule-dependent enhanced cytotoxic activity of 7-ethyl-10-hydroxy-camptothecin (SN-38) in combination with Gefitinib (Iressa, ZD1839). Biochem Pharmacol 68:135-144.
7. Bell DW, Gore I, et al. 2005. Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet 37:1315-1316.
8. Bell DW, Lynch TJ, et al. 2005. Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials. J Clin Oncol 23:8081-8092.
9. Benhar M, Engelberg D, et al. 2002. Cisplatin-induced activation of the EGF receptor. Oncogene 21:8723-8731.
10. Blackhall F, Ranson M, et al. 2006. Where next for gefitinib in patients with lung cancer? Lancet Oncol 7:499-507.
11. Blencke S, Zech B, et al. 2004. Characterization of a conserved structural determinant controlling protein kinase sensitivity to selective inhibitors. Chem Biol 11:691-701.
12. Burtness B, Goldwasser MA, et al. 2005. Phase III randomized trial of cisplatin plus placebo compared with cisplatin plus cetuximab in metastatic/recurrent head and neck cancer: an Eastern Cooperative Oncology Group study. J Clin Oncol 23:8646-8654.
13. Butts CA, Bodkin D, et al. 2007. Randomized phase II study of gemcitabine plus cisplatin, with or without cetuximab, as first-line therapy for patients with advanced or metastatic non small-cell lung cancer. J Clin Oncol 25:5777-5784.
14. Byers LA, Heymach JV. 2007. Dual targeting of the vascular endothelial growth factor and epidermal growth factor receptor pathways: rationale and clinical applications for non-small-cell lung cancer. Clin Lung Cancer 8(Suppl 2):S79-85.
15. Camp ER, Summy J, et al. 2005. Molecular mechanisms of resistance to therapies targeting the epidermal growth factor receptor. Clin Cancer Res 11:397-405.
16. Cappuzzo F, Hirsch FR, et al. 2005. Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer. J Natl Cancer Inst 97:643-655.
17. Carter TA, Wodicka LM, et al. 2005. Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci USA 102:11011-11016.
18. Chakravarti A, Loeffler JS, et al. 2002. Insulin-like growth factor receptor I mediates resistance to anti-epidermal growth factor receptor therapy in primary human glioblastoma cells through continued activation of phosphoinositide 3-kinase signaling. Cancer Res 62:200-207.
19. Chen DJ, Nirodi CS. 2007. The epidermal growth factor receptor: a role in repair of radiation-induced DNA damage. Clin Cancer Res 13(Pt 1):6555-6560.
20. Chou TY, Chiu CH, et al. 2005. Mutation in the tyrosine kinase domain of epidermal growth factor receptor is a predictive and prognostic factor for gefitinib treatment in patients with non-small cell lung cancer. Clin Cancer Res 11:3750-3757.
21. Ciardiello F, Caputo R, et al. 2000. Antitumor effect and potentiation of cytotoxic drugs activity in human cancer cells by ZD-1839 (Iressa), an epidermal growth factor receptor-selective tyrosine kinase inhibitor. Clin Cancer Res 6:2053-2063.
22. Coiffier B, Lepage E, et al. 2002. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 346:235-242.
23. Cunningham D, Humblet Y, et al. 2004. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N Engl J Med 351:337-345.
24. Davies AM, Lara PN, Lau DH, Mack PC, Gumerlock PH, Gandara DR. 2005. Intermittent erlotinib in combination with docetaxel (DOC): phase I schedules designed to achieve pharmacodynamic separation. J Clin Oncol 23 (16s): abstract 7038.
25. Discafani CM, Carroll ML, et al. 1999. Irreversible inhibition of epidermal growth factor receptor tyrosine kinase with in vivo activity by N-[4-[(3-bromophenyl)amino]-6-quinazolinyl]-2-butynamide (CL-387,785). Biochem Pharmacol 57:917-925.
26. Dittmann K, Mayer C, et al. 2005. Radiation-induced epidermal growth factor receptor nuclear import is linked to activation of DNA-dependent protein kinase. J Biol Chem 280:31182-31189.
27. Doherty L, Gigas DC, et al. 2006. Pilot study of the combination of EGFR and mTOR inhibitors in recurrent malignant gliomas. Neurology 67:156-158.
28. Dutu T, Michiels S, et al. 2005. Differential expression of biomarkers in lung adenocarcinoma: a comparative study between smokers and never-smokers. Ann Oncol 16:1906-1914.
29. Early Breast Cancer Trialists' Collaborative Group. 1998. Tamoxifen for early breast cancer: an overview of the randomised trials. Lancet 351:1451-1467.
30. Easton JB, Houghton PJ. 2004. Therapeutic potential of target of rapamycin inhibitors. Expert Opin Ther Targets 8:551-564.
31. Engelman JA, Zejnullahu K, et al. 2007a. PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res 67:11924-11932.
32. Engelman JA, Zejnullahu K, et al. 2007b. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 316:1039-1043.
33. Erlichman C, Hidalgo M, et al. 2006. Phase I study of EKB-569, an irreversible inhibitor of the epidermal growth factor receptor, in patients with advanced solid tumors. J Clin Oncol 24:2252-2260.
34. Fan QW, Knight ZA, et al. 2006. A dual PI3 kinase/mTOR inhibitor reveals emergent efficacy in glioma. Cancer Cell 9:341-349.
35. Friedmann B, Caplin M, et al. 2004. Modulation of DNA repair in vitro after treatment with chemotherapeutic agents by the epidermal growth factor receptor inhibitor gefitinib (ZD1839). Clin Cancer Res 10:6476-6486.
36. Fukuoka M, Yano S, et al. 2003. Multi-institutional randomized phase II trial of gefitinib for previously treated patients with advanced non-small-cell lung cancer (The IDEAL 1 Trial) [corrected]. J Clin Oncol 21:2237-2246.
37. Gandara DR, Davies AM, et al. 2007. Epidermal growth factor receptor inhibitors plus chemotherapy in non-small-cell lung cancer: biologic rationale for combination strategies. Clin Lung Cancer 8(Suppl 2):S61-67.
38. Gandara DR, Gumerlock PH. 2005. Epidermal growth factor receptor tyrosine kinase inhibitors plus chemotherapy: case closed or is the jury still out? J Clin Oncol 23:5856-5858.
39. Gatzemeier U, Pluzanska A, et al. 2007. Phase III study of erlotinib in combination with cisplatin and gemcitabine in advanced non-small-cell lung cancer: the Tarceva Lung Cancer Investigation Trial. J Clin Oncol 25:1545-1552.
40. Gatzemeier U, Rosell R, Ramlau R, Robinet G, Szczesna A, Quoix E, Font A, Jimenez E, Mueser M, Harstrick A. 2003. Cetuximab (C225) in combination with cisplatin/vinorelbine vs. cisplatin/vinorelbine alone int he first-line treatment of patients (pts) with epidermal growth factor receptor (EGFR) positive advanced non-small-cell lung cancer (NSCLC). Proc Am Soc Clin Oncol 22:abstract 2582.
41. Giaccone G, Herbst RS, et al. 2004. Gefitinib in combination with gemcitabine and cisplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 1. J Clin Oncol 22:777-784.
42. Gibson S, Tu S, et al. 1999. Epidermal growth factor protects epithelial cells against Fas-induced apoptosis. Requirement for Akt activation. J Biol Chem 274:17612-17618.
43. Gorre ME, Mohammed M, et al. 2001. Clinical resistance to STI-571 cancer therapy caused by BCR-ABL gene mutation or amplification. Science 293:876-880.
44. Greulich H, Chen TH, et al. 2005. Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med 2:e313.
45. Han SW, Kim TY, et al. 2005. Predictive and prognostic impact of epidermal growth factor receptor mutation in non-small-cell lung cancer patients treated with gefitinib. J Clin Oncol 23:2493-2501.
46. Han SW, Kim TY, et al. 2006. Optimization of patient selection for gefitinib in non-small cell lung cancer by combined analysis of epidermal growth factor receptor mutation, K-ras mutation, and Akt phosphorylation. Clin Cancer Res 12:2538-2544.
47. Haneda H, Sasaki H, et al. 2006. A correlation between EGFR gene mutation status and bronchioloalveolar carcinoma features in Japanese patients with adenocarcinoma. Jpn J Clin Oncol 36:69-75.
48. Hanna N, Lilenbaum R, et al. 2006. Phase II trial of cetuximab in patients with previously treated non-small-cell lung cancer. J Clin Oncol 24:5253-5258.
49. Harari PM, Allen GW, et al. 2007. Biology of interactions: antiepidermal growth factor receptor agents. J Clin Oncol 25:4057-4065.
50. Henschke CI, Yankelevitz DF, et al. 2006. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 355:1763-1771.
51. Herbst RS, Giaccone G, et al. 2004. Gefitinib in combination with paclitaxel and carboplatin in advanced non-small-cell lung cancer: a phase III trial - INTACT 2. J Clin Oncol 22:785-794.
52. Herbst RS, Johnson DH, et al. 2005. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:2544-2555.
53. Herbst RS, Prager D, et al. 2005. TRIBUTE: a phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 23:5892-5899.
54. Heymach JV, Johnson BE, et al. 2007. Randomized, placebo-controlled phase II study of vandetanib plus docetaxel in previously treated non small-cell lung cancer. J Clin Oncol 25:4270-4277.
55. Hirsch FR, Varella-Garcia M, et al. 2003. Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. J Clin Oncol 21:3798-3807.
56. Hirsch FR, Varella-Garcia M, et al. 2005. Increased epidermal growth factor receptor gene copy number detected by fluorescence in situ hybridization associates with increased sensitivity to gefitinib in patients with bronchioloalveolar carcinoma subtypes: a Southwest Oncology Group Study. J Clin Oncol 23:6838-6845.
57. Hirsch FR, Varella-Garcia M, et al. 2006. Molecular predictors of outcome with gefitinib in a phase III placebo-controlled study in advanced non-small-cell lung cancer. J Clin Oncol 24:5034-5042.
58. Hirsch FR, Varella-Garcia M, et al. 2007. Combination of EGFR gene copy number and protein expression predicts outcome for advanced non-small-cell lung cancer patients treated with gefitinib. Ann Oncol 18:752-760.
59. Hurbin A, Dubrez L, et al. 2002. Inhibition of apoptosis by amphiregulin via an insulin-like growth factor-1 receptor-dependent pathway in non-small cell lung cancer cell lines. J Biol Chem 277:49127-49133.
60. Husgafvel-Pursiainen K, Hackman P, et al. 1993. K-ras mutations in human adenocarcinoma of the lung: association with smoking and occupational exposure to asbestos. Int J Cancer 53:250-256.
61. Ihle NT, Paine-Murrieta G, et al. 2005. The phosphatidylinositol-3-kinase inhibitor PX-866 overcomes resistance to the epidermal growth factor receptor inhibitor gefitinib in A-549 human non-small cell lung cancer xenografts. Mol Cancer Ther 4:1349-1357.
62. Inoue A, Saijo Y, et al. 2003. Severe acute interstitial pneumonia and gefitinib. Lancet 361:137-139.
63. Inoue A, Suzuki T, et al. 2006. Prospective phase II study of gefitinib for chemotherapy-naive patients with advanced non-small-cell lung cancer with epidermal growth factor receptor gene mutations. J Clin Oncol 24:3340-3346.
64. Inukai M, Toyooka S, et al. 2006. Presence of epidermal growth factor receptor gene T790M mutation as a minor clone in non-small cell lung cancer. Cancer Res 66:7854-7858.
65. Janne PA, Gurubhagavatula S, et al. 2004. Outcomes of patients with advanced non-small cell lung cancer treated with gefitinib (ZD1839, Iressa) on an expanded access study. Lung Cancer 44:221-230.
66. Janne PA, Engelman JA, et al. 2005. Epidermal growth factor receptor mutations in non-small-cell lung cancer: implications for treatment and tumor biology. J Clin Oncol 23:3227-3234.
67. Johnson BE, Janne PA. 2005. Selecting patients for epidermal growth factor receptor inhibitor treatment: a FISH story or a tale of mutations? J Clin Oncol 23:6813-6816.
68. Jonker DJ, O'Callaghan CJ, et al. 2007. Cetuximab for the treatment of colorectal cancer. N Engl J Med 357:2040-2048.
69. Kantarjian H, Sawyers C, et al. 2002. Hematologic and cytogenetic responses to imatinib mesylate in chronic myelogenous leukemia. N Engl J Med 346:645-552.
70. Kelly K, Chansky K, et al. 2008. Phase III trial of maintenance gefitinib or placebo after concurrent chemoradiotherapy and docetaxel consolidation in inoperable stage III non-small-cell lung cancer: SWOG S0023. J Clin Oncol 26:2450-2456.
71. Kelly K, Herbst RS, Crowley JJ, McCoy J, Atkins JN, Lara PN, Dakhil SR, Albain KS, Kim ES, Gandara DR. 2006. Concurrent chemotherapy plus cetuximab or chemotherapy followed by cetuximab in advanced non-small cell lung cancer (NSCLC): a randomized phase II selectional trial SWOG 0342. J Clin Oncol ASCO Annual Meeting Proc Part I. 24:18S(Suppl):7015.
72. Khambata-Ford S, Garrett CR, et al. 2007. Expression of epiregulin and amphiregulin and K-ras mutation status predict disease control in metastatic colorectal cancer patients treated with cetuximab. J Clin Oncol 25:3230-3237.
73. Kim KS, Jeong JY, et al. 2005. Predictors of the response to gefitinib in refractory non-small cell lung cancer. Clin Cancer Res 11:2244-2251.
74. Kimura TM, Mahaffey CM, Pryde BJ, Mack PC, Davis AM, Gandara DR, Gumerlock PH. 2004. Apoptotic effects of the docetaxek->OSI-774 combination in non-small cell lung carcinoma (NSCLC) cells. J Clin Oncol 22 (14S): abstract 7143.
75. Kobayashi S, Boggon TJ, et al. 2005. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med 352:786-792.
76. Kosaka T, Yatabe Y, et al. 2004. Mutations of the epidermal growth factor receptor gene in lung cancer: biological and clinical implications. Cancer Res 64:8919-8923.
77. Krause DS, Van Etten RA. 2005. Tyrosine kinases as targets for cancer therapy. N Engl J Med 353:172-187.
78. Kris MG, Natale RB, et al. 2003. Efficacy of gefitinib, an inhibitor of the epidermal growth factor receptor tyrosine kinase, in symptomatic patients with non-small cell lung cancer: a randomized trial. JAMA 290:2149-2158.
79. Kwak EL, Sordella R, et al. 2005. Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci USA 102:7665-7670.
80. Lilenbaum RC. 2006. The evolving role of cetuximab in non-small cell lung cancer. Clin Cancer Res 12(Pt 2):4432s-4435s.
81. Lin SY, Makino K, et al. 2001. Nuclear localization of EGF receptor and its potential new role as a transcription factor. Nat Cell Biol 3:802-808.
82. Lynch TJ. 2007. 12th World Conference on Lung Cancer. Abstract B303.
83. Lynch TJ, Bell DW, et al. 2004. Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med 350:2129-2139.
84. Marchetti A, Martella C, et al. 2005. EGFR mutations in non-small-cell lung cancer: analysis of a large series of cases and development of a rapid and sensitive method for diagnostic screening with potential implications on pharmacologic treatment. J Clin Oncol 23:857-865.
85. Massarelli E, Andre F, et al. 2003. A retrospective analysis of the outcome of patients who have received two prior chemotherapy regimens including platinum and docetaxel for recurrent non-small-cell lung cancer. Lung Cancer 39:55-61.
86. Mendelsohn J. 1997. Epidermal growth factor receptor inhibition by a monoclonal antibody as anticancer therapy. Clin Cancer Res 3(Pt 2):2703-2707.
87. Mendelsohn J, Fan Z. 1997. Epidermal growth factor receptor family and chemosensitization. J Natl Cancer Inst 89:341-343.
88. Miller VA, Riely GJ, et al. 2008. Molecular characteristics of bronchioloalveolar carcinoma and adenocarcinoma, bronchioloalveolar carcinoma subtype, predict response to erlotinib. J Clin Oncol 26:1472-1478.
89. Mitsudomi T, Steinberg SM, et al. 1991. Ras gene mutations in non-small cell lung cancers are associated with shortened survival irrespective of treatment intent. Cancer Res 51:4999-5002.
90. Mitsudomi T, Kosaka T, et al. 2005. Mutations of the epidermal growth factor receptor gene predict prolonged survival after gefitinib treatment in patients with non-small-cell lung cancer with postoperative recurrence. J Clin Oncol 23:2513-5220.
91. Moore MJ, Goldstein D, et al. 2007. Erlotinib plus gemcitabine compared with gemcitabine alone in patients with advanced pancreatic cancer: a phase III trial of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 25:1960-1966.
92. Moroni M, Veronese S, et al. 2005. Gene copy number for epidermal growth factor receptor (EGFR) and clinical response to antiEGFR treatment in colorectal cancer: a cohort study. Lancet Oncol 6:279-286.
93. Mukohara T, Engelman JA, et al. 2005. Differential effects of gefitinib and cetuximab on non-small-cell lung cancers bearing epidermal growth factor receptor mutations. J Natl Cancer Inst 97:1185-1194.
94. Nicholson RI, Gee JM, et al. 2001. EGFR and cancer prognosis. Eur J Cancer 37(Suppl 4):S9-15.
95. Nyati MK, Morgan MA, et al. 2006. Integration of EGFR inhibitors with radiochemotherapy. Nat Rev Cancer 6:876-885.
96. Ohsaki Y, Tanno S, et al. 2000. Epidermal growth factor receptor expression correlates with poor prognosis in non-small cell lung cancer patients with p53 overexpression. Oncol Rep 7:603-607.
97. P, Oc, Modjtahedi H, et al. 2000. Epidermal growth factor-like ligands differentially up-regulate matrix metalloproteinase 9 in head and neck squamous carcinoma cells. Cancer Res 60:1121-1128.
98. Paez JG, Janne PA, et al. 2004. EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science 304:1497-1500.
99. Pao W, Miller V, et al. 2004. EGF receptor gene mutations are common in lung cancers from never smokers and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci USA 101:13306-13311.
100. Pao W, Miller VA, et al. 2005a. Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med 2:e73.
101. Pao W, Wang TY, et al. 2005b. KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib. PLoS Med 2:e17.
102. Paz-Ares LS, Sanchez JM, Garcia-Velasco A, Massuti B, Lopez-Vivanco G, Provencio M, Montes A, Isla D, Amador ML, Rosell R. 2006. A prospective phase II trial of erlotinib in advanced non-small-cell lung cancer (NSCLC) patients (p) with mutations in the tyrosine kinase (TK) domain of the epidermal growth factor receptor (EGFR). J Clin Oncol 24(18S): abstract 7020.
103. Perez-Soler R, Chachoua A, et al. 2004. Determinants of tumor response and survival with erlotinib in patients with non-small-cell lung cancer. J Clin Oncol 22:3238-3247.
104. Petit AM, Rak J, et al. 1997. Neutralizing antibodies against epidermal growth factor and ErbB-2/neu receptor tyrosine kinases down-regulate vascular endothelial growth factor production by tumor cells in vitro and in vivo: angiogenic implications for signal transduction therapy of solid tumors. Am J Pathol 151:1523-1530.
105. Pirker R, Szczesna A, von Pawl J, Krzakowski M, Ramlau R, Park K, Gatzemeier U, Bajeta E, Emig M, Pereira JR. 2008. FLEX: a randomized, multicenter, phase III study of cetuximab in combination with cisplatin/vinorelbine (CV) versus CV alone in the first-line treatment of patients with advanced non-small cell lung cancer (NSCLC). J Clin Oncol 26: abstract 3.
106. Prenzel N, Fischer OM, et al. 2001. The epidermal growth factor receptor family as a central element for cellular signal transduction and diversification. Endocr Relat Cancer 8:11-31.
107. Prewett M, Rockwell P, et al. 1996. The biologic effects of C225, a chimeric monoclonal antibody to the EGFR, on human prostate carcinoma. J Immunother Emphasis Tumor Immunol 19:419-427.
108. Raez LE, Lopes G, et al. 2005. Clinical responses to gefinitib after failure of treatment with cetuximab in advanced non-small-cell lung cancer. J Clin Oncol 23:4244-4245.
109. Robert F, Blumenschein G, et al. 2005. Phase I/IIa study of cetuximab with gemcitabine plus carboplatin in patients with chemotherapy-naive advanced non-small-cell lung cancer. J Clin Oncol 23:9089-9096.
110. Rodenhuis S, van de Wetering ML, et al. 1987. Mutational activation of the K-ras oncogene. A possible pathogenetic factor in adenocarcinoma of the lung. N Engl J Med 317:929-935.
111. Rosell R, Robinet G, et al. 2008. Randomized phase II study of cetuximab plus cisplatin/vinorelbine compared with cisplatin/vinorelbine alone as first-line therapy in EGFR-expressing advanced non-small-cell lung cancer. Ann Oncol 19:362-369.
112. Rubin BP, Duensing A. 2006. Mechanisms of resistance to small molecule kinase inhibition in the treatment of solid tumors. Lab Invest 86:981-986.
113. Rubin Grandis J, Melhem MF, et al. 1998. Levels of TGF-alpha and EGFR protein in head and neck squamous cell carcinoma and patient survival. J Natl Cancer Inst 90:824-832.
114. Rusch V, Baselga J, et al. 1993. Differential expression of the epidermal growth factor receptor and its ligands in primary non-small cell lung cancers and adjacent benign lung. Cancer Res 53(Suppl):2379-2385.
115. Salomon DS, Brandt R, et al. 1995. Epidermal growth factor-related peptides and their receptors in human malignancies. Crit Rev Oncol Hematol 19:183-232.
116. Saltz LB, Meropol NJ, et al. 2004. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor. J Clin Oncol 22:1201-1208.
117. Schiller JH, Harrington D, et al. 2002. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346:92-98.
118. Schreiber AB, Winkler ME, et al. 1986. Transforming growth factor-alpha: a more potent angiogenic mediator than epidermal growth factor. Science 232:1250-1253.
119. Sequist LV. 2007. Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist 12:325-330.
120. Sequist LV, Bell DW, et al. 2007. Molecular predictors of response to epidermal growth factor receptor antagonists in non-small-cell lung cancer. J Clin Oncol 25:587-595.
121. Sequist LV, Lynch TJ. 2008. EGFR tyrosine kinase inhibitors in lung cancer: an evolving story. Annu Rev Med 59:429-442.
122. Sequist LV, Martins RG, et al. 2008. First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations. J Clin Oncol 26:2442-2449.
123. Sharma SV, Bell DW, et al. 2007. Epidermal growth factor receptor mutations in lung cancer. Nat Rev Cancer 7:169-181.
124. Shepherd FA, Dancey J, et al. 2000. Prospective randomized trial of docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy. J Clin Oncol 18:2095-2103.
125. Shepherd FA, Rodrigues Pereira J, et al. 2005. Erlotinib in previously treated non-small-cell lung cancer. N Engl J Med 353:123-132.
126. Shibuya K, Komaki R, et al. 2007. Targeted therapy against VEGFR and EGFR with ZD6474 enhances the therapeutic efficacy of irradiation in an orthotopic model of human non-small-cell lung cancer. Int J Radiat Oncol Biol Phys 69:1534-1543.
127. Shigematsu H, Lin L, et al. 2005. Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. J Natl Cancer Inst 97:339-346.
128. Sirotnak FM, Zakowski MF, et al. 2000. Efficacy of cytotoxic agents against human tumor xenografts is markedly enhanced by coadministration of ZD1839 (Iressa), an inhibitor of EGFR tyrosine kinase. Clin Cancer Res 6:4885-4892.
129. Smaill JB, Rewcastle GW, et al. 2000. Tyrosine kinase inhibitors. 17. Irreversible inhibitors of the epidermal growth factor receptor: 4-(phenylamino)quinazoline- and 4-(phenylamino)pyrido[3,2-d]pyrimidine-6- acrylamides bearing additional solubilizing functions. J Med Chem 43:1380-1397.
130. Sumitomo M, Asano T, et al. 2004. ZD1839 modulates paclitaxel response in renal cancer by blocking paclitaxel-induced activation of the epidermal growth factor receptor-extracellular signal-regulated kinase pathway. Clin Cancer Res 10:794-801.
131. Tabernero J. 2007. The role of VEGF and EGFR inhibition: implications for combining anti-VEGF and anti-EGFR agents. Mol Cancer Res 5:203-220.
132. Takano T, Ohe Y, et al. 2005. Epidermal growth factor receptor gene mutations and increased copy numbers predict gefitinib sensitivity in patients with recurrent non-small-cell lung cancer. J Clin Oncol 23:6829-6837.
133. Thatcher N, Chang A, et al. 2005. Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer). Lancet 366:1527-1537.
134. Thienelt CD, Bunn Jr PA, et al. 2005. Multicenter phase I/II study of cetuximab with paclitaxel and carboplatin in untreated patients with stage IV non-small-cell lung cancer. J Clin Oncol 23:8786-8793.
135. Tsao MS, Sakurada A, et al. 2005. Erlotinib in lung cancer - molecular and clinical predictors of outcome. N Engl J Med 353:133-144.
136. Van Cutsem E, Peeters M, et al. 2007. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 25:1658-1664.
137. Veronese ML, Algazy K, et al. 2005. Gefitinib in patients with advanced non-small cell lung cancer (NSCLC): the expanded access protocol experience at the University of Pennsylvania. Cancer Invest 23:296-302.
138. Wacker B, Nagrani T, et al. 2007. Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 13:3913-3921.
139. Weinstein IB. 2002. Cancer. Addiction to oncogenes - the Achilles heal of cancer. Science 297:63-64.
140. Weinstein IB, Joe AK. 2006. Mechanisms of disease: oncogene addiction - a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol 3:448-457.
141. Yang CH, Yu CJ, et al. 2008. Specific EGFR mutations predict treatment outcome of stage IIIB/IV patients with chemotherapy-naive non-small-cell lung cancer receiving first-line gefitinib monotherapy. J Clin Oncol 26:2745-2753.
142. Yun CH, Boggon TJ, et al. 2007. Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell 11:217-227.
143. Zhang W, Gordon M, et al. 2006. Cyclin D1 and epidermal growth factor polymorphisms associated with survival in patients with advanced colorectal cancer treated with Cetuximab. Pharmacogenet Genomics 16:475-483.
144. Zhang W, Gordon M, et al. 2007. FCGR2A and FCGR3A polymorphisms associated with clinical outcome of epidermal growth factor receptor expressing metastatic colorectal cancer patients treated with single-agent cetuximab. J Clin Oncol 25:3712-3718.